fda warning letters compounded semaglutide tirzepatide 2025 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our FDA Issues Warning Letters to

If diet changes and workouts are no longer moving the scale, tirzepatide is one of the few weight loss medications with a strong clinical track record behind it

Product: How to Store Tirzepatide: Tips for Proper Refrigeration Proper storage of tirzepatide ( is essential to preserve its efficacy and ensure patient safety

But in reality, almost everyone has dark lips

Reduced Sweating (Anhidrosis): Some individuals with diabetes experience reduced sweating, making it difficult to cool down in hot weather

Transparency in the Enough Era The question Did Oprah use Ozempic? was a major theme of the 2025 and 2026 media cycles

Shared decision-making remains central